logo
Sign in

VRCA Stock Price, Chart, Stats & News

Verrica Pharmaceuticals Inc.
Save
62.31M
Market cap
Current P/E
Forward P/E

VRCA chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
90.80%
Operating margin
-33.56%
Pretax margin
-50.27%
Net margin
-50.27%
Effective tax rate
ROA
-37.95%
ROE
252.30%
D/E
0.07x
Interest coverage ratio
-1.54x

VRCA valuation

P/E
P/S
1.31x
P/B
1.89x
P/CF
-2.65x
P/FCF
-2.65x
P/OCF
-2.65x
PEG
-0.05x
EV multiple
-6.74x

About

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications.

Similar securities

Based on sector and market capitalization

Report issue